These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38014450)
21. Amyloid A amyloidosis in a patient with Caplan's syndrome, with special reference to genetic predisposition. Nakamura T; Shiraishi N; Morikami Y; Fujii H; Yoshinaga T Mod Rheumatol Case Rep; 2020 Jul; 4(2):212-217. PubMed ID: 33087017 [TBL] [Abstract][Full Text] [Related]
22. [Autoinflammatory syndromes and AA amyloidosis]. Blank N; Schönland SO Z Rheumatol; 2020 Sep; 79(7):649-659. PubMed ID: 32253511 [TBL] [Abstract][Full Text] [Related]
23. AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of "monoclonal gammopathy of inflammatory significance"? Terré A; Colombat M; Cez A; Martin C; Diet C; Brechignac S; Oghina S; Bodez D; Faguer S; Savey L; Galland J; Boffa JJ; Grateau G; Jaccard A; Buob D; Georgin-Lavialle S Int J Clin Pract; 2021 Nov; 75(11):e14817. PubMed ID: 34490695 [TBL] [Abstract][Full Text] [Related]
24. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Stankovic Stojanovic K; Delmas Y; Torres PU; Peltier J; Pelle G; Jéru I; Colombat M; Grateau G Nephrol Dial Transplant; 2012 May; 27(5):1898-901. PubMed ID: 21931121 [TBL] [Abstract][Full Text] [Related]
25. Gastric AA amyloidosis secondary to chronic infection presenting with hematemesis: a case report. Huang Y; Nasir S; Challa SR; Peng CC; Stashek K; Fanaroff R; Hu S Clin J Gastroenterol; 2020 Dec; 13(6):1070-1073. PubMed ID: 32852723 [TBL] [Abstract][Full Text] [Related]
26. Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Karam S; Haidous M; Royal V; Leung N Kidney Int; 2023 Mar; 103(3):473-484. PubMed ID: 36502873 [TBL] [Abstract][Full Text] [Related]
27. Cervical cancer of the uterus complicated by renal AA amyloidosis. Fujisawa H; Ohashi A; Ohta J; Muraki N; Nakano Y; Sugita K; Ishihara S; Kumagai J; Fukutomi T; Nagahama K CEN Case Rep; 2021 Feb; 10(1):115-120. PubMed ID: 32910374 [TBL] [Abstract][Full Text] [Related]
28. Living kidney transplantation between brothers with unrecognized renal amyloidosis as the first manifestation of familial Mediterranean fever: a case report. Peces R; Afonso S; Peces C; Nevado J; Selgas R BMC Med Genet; 2017 Aug; 18(1):97. PubMed ID: 28859624 [TBL] [Abstract][Full Text] [Related]
29. Late Acute Cellular Rejection After Anakinra Treatment in a Kidney Transplant Patient, Is It a Coincidence? Yeter HH; Yetkin N; Akcay O; Derici U; Arinsoy T Iran J Kidney Dis; 2020 Jul; 14(4):318-320. PubMed ID: 32655029 [TBL] [Abstract][Full Text] [Related]
30. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis. Kuroda T; Tanabe N; Hasegawa E; Wakamatsu A; Nozawa Y; Sato H; Nakatsue T; Wada Y; Ito Y; Imai N; Ueno M; Nakano M; Narita I Amyloid; 2017 Jun; 24(2):123-130. PubMed ID: 28613962 [TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Lane T; Wechalekar AD; Gillmore JD; Hawkins PN; Lachmann HJ Amyloid; 2017 Sep; 24(3):189-193. PubMed ID: 28745926 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Alpay N; Sumnu A; Calışkan Y; Yazıcı H; Türkmen A; Gül A Rheumatol Int; 2012 Oct; 32(10):3277-9. PubMed ID: 20386914 [TBL] [Abstract][Full Text] [Related]
33. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Bilginer Y; Ayaz NA; Ozen S Clin Rheumatol; 2010 Feb; 29(2):209-10. PubMed ID: 19774408 [TBL] [Abstract][Full Text] [Related]
34. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report . Yamada Y; Ueno T; Irifuku T; Nakashima A; Doi S; Ichinohe T; Masaki T Clin Nephrol; 2018 Sep; 90(3):232-236. PubMed ID: 29701172 [TBL] [Abstract][Full Text] [Related]
35. Retroperitoneal paraganglioma and systemic amyloidosis: a case report. Rey C; Escribano JC; Vidal MT Cancer; 1979 Feb; 43(2):702-6. PubMed ID: 421189 [TBL] [Abstract][Full Text] [Related]
36. Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature. Jung JY; Kim YB; Kim JW; Suh CH; Kim HA Medicine (Baltimore); 2021 Aug; 100(32):e26843. PubMed ID: 34397890 [TBL] [Abstract][Full Text] [Related]
37. Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis. Almenara-Tejederas M; Alonso-García F; Aguillera-Morales WA; de la Prada-Álvares F; Salgueira-Lazo M Nefrologia (Engl Ed); 2022; 42(1):28-32. PubMed ID: 36153896 [TBL] [Abstract][Full Text] [Related]
40. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Perry ME; Stirling A; Hunter JA Clin Rheumatol; 2008 Jul; 27(7):923-5. PubMed ID: 18379834 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]